 |
|
Evaluation of Migraineurs' Preferences for Naratriptan Over Conventional First-Line Agents
Charles Powers, MD;
Simon Szeto, MD;
Dennis Pangtay, MD;
Thaddeus Bort, MD;
Mark Cervi, MD;
Roger Cady, MD
Arch Fam Med. 2000;9:753-757.
Objective To assess patient satisfaction with and preference for naratriptan hydrochloride therapy over previous "nontriptan" therapy for migraines.
Design and Setting Open-label study conducted at 15 primary care clinics.
Patients One hundred forty-three adults meeting International Headache Society diagnostic criteria for migraine who were not using triptans as first-line therapy for migraines were enrolled; 115 completed the study.
Intervention and Outcome Assessments At baseline, satisfaction with current migraine therapy was assessed. Patients were provided with naratriptan hydrochloride, 2.5 mg, to treat 3 migraines and diaries to record headache symptoms and response to treatment. After treating 3 migraines, satisfaction with naratriptan therapy and preference for either previous or naratriptan therapy were assessed.
Results Eighty-nine (62%) of 143 patients had previous exposure to triptans, with lack of prescribing (55%) as the primary reason for not continuing their use as first-line therapy. Medications used for first-line therapy included simple analgesics (59%), combination products (46%), and narcotics (13%). After treating 3 migraines with naratriptan, satisfaction with migraine therapy increased from 47% to 75%. Sixty-three percent of patients preferred naratriptan therapy over their previous nontriptan therapy, 27% preferred their previous therapy, and 10% had no preference. The main reasons for preference for naratriptan therapy were "relieves pain effectively" (86%) and "restores ability to function/perform task" (81%).
Conclusion Naratriptan for first-line migraine therapy was preferred by most patients over previous nontriptan therapy.
From Family Practice–St Cloud, St Cloud, Fla (Dr Powers); Blue Ridge Clinic, Independence, Mo (Dr Szeto); Medical and Surgical of Irving, Irving, Tex (Dr Pangtay); Greater Cincinnati Associated Physicians, Cincinnati, Ohio (Dr Bort); Carolina Internal Medicine, Greenville, NC (Dr Cervi); and Headache Care Center, Springfield, Mo (Dr Cady). Drs Powers and Cervi are on the speakers' bureau for Glaxo Wellcome Inc, Research Triangle Park, NC. Dr Szeto has done consulting and research for and is a stock owner of Glaxo Wellcome, Inc. Dr Cady is involved in research, advisory boards, and the speakers' bureau for Glaxo Wellcome Inc.
RELATED ARTICLES
The Archives of Family Medicine Continuing Medical Education Program
Arch Fam Med. 2000;9(8):735.
FULL TEXT
Editor's Comment
Marjorie A. Bowman
Arch Fam Med. 2000;9(8):758.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Pediatric Palliative Care: A Novel Approach to Children With Sickle Cell Disease
McClain and Kain
Pediatrics 2007;119:612-614.
FULL TEXT
Patient Satisfaction with Migraine Management by Family Physicians
Walling et al.
J Am Board Fam Med 2005;18:563-566.
ABSTRACT
| FULL TEXT
Patient Treatment Preferences and the 5-HT1B/1D Agonists
Ryan
Arch Intern Med 2001;161:2545-2553.
ABSTRACT
| FULL TEXT
|
